Pipeline

We take aim at the world’s most intractable diseases. Our portfolio spans both novel and known (but traditionally undruggable) targets.

Indication

rModality

Target

Discovery

Pre-clinical

Clinical

IL-2

Cancer & Metabolic

MYC

Cancer & Immunity

Inflamm. & Immunity

SM

SM

SM

SM

SM

ASO

SM

SM

FLCN

Cancer & Immunity

Inflamm. & Immunity

IL-1β

SM

SM

FLCN

RAS

FLCN

ALS

FTD/AD

Cancer

ALS

IL-1α

IL-1RA

PTPN2

Inflamm. & Immunity

SM = small molecule
rModality = RNA-targeted modality